JP2015508075A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015508075A5 JP2015508075A5 JP2014556711A JP2014556711A JP2015508075A5 JP 2015508075 A5 JP2015508075 A5 JP 2015508075A5 JP 2014556711 A JP2014556711 A JP 2014556711A JP 2014556711 A JP2014556711 A JP 2014556711A JP 2015508075 A5 JP2015508075 A5 JP 2015508075A5
- Authority
- JP
- Japan
- Prior art keywords
- pyrido
- pyrimidin
- methyl
- pyrazin
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261597523P | 2012-02-10 | 2012-02-10 | |
| US61/597,523 | 2012-02-10 | ||
| PCT/US2013/025292 WO2013119916A2 (en) | 2012-02-10 | 2013-02-08 | Compounds for treating spinal muscular atrophy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017022640A Division JP6363744B2 (ja) | 2012-02-10 | 2017-02-09 | 脊髄性筋萎縮症を治療するための化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015508075A JP2015508075A (ja) | 2015-03-16 |
| JP2015508075A5 true JP2015508075A5 (enExample) | 2016-03-03 |
| JP6092897B2 JP6092897B2 (ja) | 2017-03-08 |
Family
ID=48948163
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014556711A Active JP6092897B2 (ja) | 2012-02-10 | 2013-02-08 | 脊髄性筋萎縮症を治療するための化合物 |
| JP2017022640A Active JP6363744B2 (ja) | 2012-02-10 | 2017-02-09 | 脊髄性筋萎縮症を治療するための化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017022640A Active JP6363744B2 (ja) | 2012-02-10 | 2017-02-09 | 脊髄性筋萎縮症を治療するための化合物 |
Country Status (29)
| Country | Link |
|---|---|
| US (6) | US9586955B2 (enExample) |
| EP (2) | EP2812004B1 (enExample) |
| JP (2) | JP6092897B2 (enExample) |
| KR (2) | KR102137087B1 (enExample) |
| CN (3) | CN119528903A (enExample) |
| AR (1) | AR092794A1 (enExample) |
| AU (2) | AU2013216870B2 (enExample) |
| BR (1) | BR112014019750B1 (enExample) |
| CA (1) | CA2863874C (enExample) |
| CL (1) | CL2014002100A1 (enExample) |
| CO (1) | CO7061082A2 (enExample) |
| CR (1) | CR20140376A (enExample) |
| DK (1) | DK2812004T3 (enExample) |
| EA (2) | EA037123B1 (enExample) |
| EC (1) | ECSP14017269A (enExample) |
| ES (1) | ES2697174T3 (enExample) |
| HU (1) | HUE039779T2 (enExample) |
| IL (2) | IL233959A (enExample) |
| MA (1) | MA35920B1 (enExample) |
| MX (2) | MX354074B (enExample) |
| NZ (1) | NZ628186A (enExample) |
| PE (1) | PE20142364A1 (enExample) |
| PH (2) | PH12018501711B1 (enExample) |
| PL (1) | PL2812004T3 (enExample) |
| SG (2) | SG10201609188WA (enExample) |
| TR (1) | TR201813877T4 (enExample) |
| TW (2) | TWI629274B (enExample) |
| UA (1) | UA116981C2 (enExample) |
| WO (1) | WO2013119916A2 (enExample) |
Families Citing this family (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10327940B2 (en) | 2008-11-09 | 2019-06-25 | 3D Systems, Inc. | Spiral brace |
| KR102057351B1 (ko) | 2011-12-30 | 2019-12-18 | 피티씨 테라퓨틱스, 인크. | 척수성 근위축증을 치료하기 위한 화합물 |
| PL2809322T3 (pl) | 2012-01-26 | 2019-11-29 | Ptc Therapeutics Inc | Związki do leczenia zaniku mięśni pochodzenia rdzeniowego |
| DK2812004T3 (en) * | 2012-02-10 | 2018-10-15 | Ptc Therapeutics Inc | COMPOUNDS FOR TREATMENT OF SPINAL MUSCLE DROPHY |
| CN104302181B (zh) | 2012-03-01 | 2017-09-15 | Ptc医疗公司 | 用于治疗脊髓性肌萎缩的化合物 |
| KR102109992B1 (ko) | 2012-03-23 | 2020-05-13 | 피티씨 테라퓨틱스, 인크. | 척수성 근위축증을 치료하기 위한 화합물 |
| KR20150098675A (ko) * | 2012-12-24 | 2015-08-28 | 라모트 앳 텔-아비브 유니버시티 리미티드 | 넌센스 돌연변이로부터 생긴 유전적 질환을 치료하기 위한 물질 및 이를 확인하는 방법 |
| WO2015024876A2 (en) * | 2013-08-19 | 2015-02-26 | F. Hoffmann-La Roche Ag | Screening method |
| EP3082820B1 (en) | 2013-12-19 | 2022-07-20 | PTC Therapeutics, Inc. | Methods for modulating the amount of rna transcripts |
| SI3143025T1 (sl) * | 2014-05-15 | 2020-01-31 | F. Hoffmann-La Roche Ag | Spojine za zdravljenje spinalne mišične atrofije |
| US10882868B2 (en) | 2014-05-15 | 2021-01-05 | Hoffmann-La Roche Inc. | Compounds for treating spinal muscular atrophy |
| GB201410693D0 (en) | 2014-06-16 | 2014-07-30 | Univ Southampton | Splicing modulation |
| US10436802B2 (en) | 2014-09-12 | 2019-10-08 | Biogen Ma Inc. | Methods for treating spinal muscular atrophy |
| AU2015327836B2 (en) | 2014-10-03 | 2021-07-01 | Cold Spring Harbor Laboratory | Targeted augmentation of nuclear gene output |
| ES2879809T3 (es) * | 2014-11-01 | 2021-11-23 | Shanghai Fochon Pharmaceutical Co Ltd | Ciertos inhibidores de proteínas quinasas |
| EP3242763A4 (en) * | 2015-01-05 | 2018-08-29 | Sikorsky Aircraft Corporation | Integrated vibration damper for additively manufactured structure and method |
| EP3298017B1 (en) | 2015-05-20 | 2019-08-14 | H. Hoffnabb-La Roche Ag | Compounds for treating spinal muscular atrophy |
| EP4249472A3 (en) | 2015-05-30 | 2023-12-13 | PTC Therapeutics, Inc. | Methods for modulating rna splicing |
| CN108603230A (zh) | 2015-10-09 | 2018-09-28 | 南安普敦大学 | 基因表达的调节与蛋白质表达失调的筛选 |
| JP6659841B2 (ja) | 2015-11-12 | 2020-03-04 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 脊髄性筋萎縮症を処置するための組成物 |
| WO2017081111A1 (en) * | 2015-11-12 | 2017-05-18 | F. Hoffmann-La Roche Ag | Compounds for treating amyotrophic lateral sclerosis |
| JP7071917B2 (ja) | 2015-12-09 | 2022-05-19 | カデント セラピューティクス，インコーポレーテッド | ヘテロ芳香族ｎｍｄａ受容体モジュレーターおよびその使用 |
| IL294124B2 (en) | 2015-12-10 | 2024-02-01 | Ptc Therapeutics Inc | Methods for treating huntington's disease |
| WO2017097728A1 (en) | 2015-12-10 | 2017-06-15 | F. Hoffmann-La Roche Ag | Bridged piperidine derivatives |
| US11096956B2 (en) | 2015-12-14 | 2021-08-24 | Stoke Therapeutics, Inc. | Antisense oligomers and uses thereof |
| WO2017106377A1 (en) | 2015-12-14 | 2017-06-22 | Cold Spring Harbor Laboratory | Antisense oligomers for treatment of autosomal dominant mental retardation-5 and dravet syndrome |
| JP6983813B2 (ja) * | 2016-04-28 | 2021-12-17 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | ２−ピラゾロ［１，５−ａ］ピラジン−２−イルピリド［１，２−ａ］ピリミジン−４−オンの調製のためのプロセス |
| US11198867B2 (en) | 2016-06-16 | 2021-12-14 | Ionis Pharmaceuticals, Inc. | Combinations for the modulation of SMN expression |
| EA201991309A1 (ru) * | 2016-11-28 | 2019-11-29 | Способы модуляции сплайсинга рнк | |
| US11274107B2 (en) | 2016-12-22 | 2022-03-15 | Cadent Therapeutics, Inc. | NMDA receptor modulators and uses thereof |
| US11407753B2 (en) | 2017-06-05 | 2022-08-09 | Ptc Therapeutics, Inc. | Compounds for treating Huntington's disease |
| KR20200017476A (ko) | 2017-06-14 | 2020-02-18 | 피티씨 테라퓨틱스, 인크. | Rna 스플라이싱의 변경 방법 |
| US11382918B2 (en) | 2017-06-28 | 2022-07-12 | Ptc Therapeutics, Inc. | Methods for treating Huntington's Disease |
| WO2019005993A1 (en) * | 2017-06-28 | 2019-01-03 | Ptc Therapeutics, Inc. | METHODS OF TREATING HUNTINGTON'S DISEASE |
| WO2019028440A1 (en) | 2017-08-04 | 2019-02-07 | Skyhawk Therapeutics, Inc. | METHODS AND COMPOSITIONS FOR MODULATING SPLICING |
| KR102318434B1 (ko) | 2017-08-25 | 2021-11-01 | 스톡 테라퓨틱스, 인크. | 병태 및 질환 치료용 안티센스 올리고머 |
| HRP20251594T1 (hr) * | 2017-09-22 | 2026-01-30 | F. Hoffmann - La Roche Ag | Postupak priprave derivata 7-(4,7-diazaspiro[2.5]oktan-7-il)-2-(2,8-dimetilimidazo[1,2-b]piridazin-6-il)pirido[1,2-a]pirimidin-4-ona |
| HUE070436T2 (hu) | 2017-10-23 | 2025-06-28 | Stoke Therapeutics Inc | Antiszensz oligomerek nonszensz-mediált RNS-lebomláson alapuló állapotok és betegségek kezelésére |
| MX2020009957A (es) | 2018-03-27 | 2021-01-15 | Ptc Therapeutics Inc | Compuestos para el tratamiento de enfermedad de hungtinton. |
| CA3099280A1 (en) | 2018-05-04 | 2019-11-07 | Stoke Therapeutics, Inc. | Methods and compositions for treatment of cholesteryl ester storage disease |
| EP3814345B8 (en) | 2018-06-27 | 2024-10-30 | PTC Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
| BR112020026637A2 (pt) * | 2018-06-27 | 2021-03-30 | Reborna Biosciences, Inc. | Agente profilático ou terapêutico para atrofia muscular espinhal |
| PL3814357T3 (pl) | 2018-06-27 | 2024-09-16 | Ptc Therapeutics, Inc. | Związki heterocykliczne i heteroarylowe do leczenia choroby huntingtona |
| EP3814360B8 (en) | 2018-06-27 | 2024-11-06 | PTC Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
| AR115905A1 (es) | 2018-08-03 | 2021-03-10 | Cadent Therapeutics Inc | 5-(3-cloro-4-fluorofenil)-7-ciclopropil-3-(2-(3-fluoro-3-metilazetidin-1-il)-2-oxoetil)-3,7-dihidro-4h-pirrolo[2,3-d]pirimidin-4-ona como modulador de los receptores de nmda |
| US20210355509A1 (en) * | 2018-08-07 | 2021-11-18 | The Children's Hospital Of Philadelphia | Alternative splicing regulation of gene expression and therapeutic methods |
| WO2020163248A1 (en) | 2019-02-04 | 2020-08-13 | Skyhawk Therapeutics, Inc. | Methods and compositions for modulating splicing |
| CN114126613A (zh) | 2019-02-05 | 2022-03-01 | 斯基霍克疗法公司 | 用于调节剪接的方法和组合物 |
| EP3920915A4 (en) | 2019-02-05 | 2022-10-05 | Skyhawk Therapeutics, Inc. | METHODS AND COMPOSITIONS FOR MODULATING SPLICE |
| CN113661162A (zh) | 2019-02-06 | 2021-11-16 | 斯基霍克疗法公司 | 用于调节剪接的方法和组合物 |
| WO2020163544A1 (en) | 2019-02-06 | 2020-08-13 | Skyhawk Therapeutics, Inc. | Methods and compositions for modulating splicing |
| AU2020227825B2 (en) | 2019-02-27 | 2026-03-26 | Stoke Therapeutics, Inc. | Antisense oligomers for treatment of conditions and diseases |
| WO2020231977A1 (en) | 2019-05-13 | 2020-11-19 | Ptc Therapeutics, Inc. | Compounds for treating huntington's disease |
| US11129829B2 (en) | 2019-06-17 | 2021-09-28 | Skyhawk Therapeutics, Inc. | Methods for modulating splicing |
| EP4004003A1 (en) | 2019-07-31 | 2022-06-01 | Teva Pharmaceuticals International GmbH | Solid state forms of risdiplam and process for preparation thereof |
| CN110540535B (zh) * | 2019-10-23 | 2020-07-31 | 上海再启生物技术有限公司 | 适合放大制备4-(6-氨基吡啶-3-基)取代哌啶的工艺方法 |
| CN111116576A (zh) * | 2019-12-01 | 2020-05-08 | 北京师范大学 | 一种喹嗪酮类化合物及其制备方法 |
| CN115151540A (zh) | 2019-12-02 | 2022-10-04 | 风暴治疗有限公司 | 作为mettl3抑制剂的多杂环化合物 |
| EP4097092A1 (en) | 2020-01-28 | 2022-12-07 | Protego Biopharma, Inc. | Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding |
| CN115605596A (zh) * | 2020-02-12 | 2023-01-13 | 费城儿童医院（Us） | 用于基因表达的诱导型可变剪接调节的组合物和方法 |
| JP7736700B2 (ja) | 2020-02-28 | 2025-09-09 | リミックス セラピューティクス インコーポレイテッド | 複素環アミド及びスプライシングを調節するためのその使用 |
| WO2021174167A1 (en) | 2020-02-28 | 2021-09-02 | Remix Therapeutics Inc. | Compounds and methods for modulating splicing |
| CN120505310A (zh) | 2020-02-28 | 2025-08-19 | Ionis制药公司 | 用于调节smn2的化合物和方法 |
| MX2022010634A (es) | 2020-02-28 | 2023-01-19 | Remix Therapeutics Inc | Derivados de piridazina para modular el empalme de acidos nucleicos. |
| CA3169697A1 (en) | 2020-02-28 | 2021-09-02 | Dominic Reynolds | Thiophenyl derivatives useful for modulating nucleic acid splicing |
| JP2023520916A (ja) | 2020-04-08 | 2023-05-22 | リミックス セラピューティクス インコーポレイテッド | スプライシングを調整するための化合物及び方法 |
| KR20230005210A (ko) | 2020-04-08 | 2023-01-09 | 레믹스 테라퓨틱스 인크. | 스플라이싱을 조절하기 위한 화합물 및 방법 |
| CN115867657A (zh) | 2020-05-11 | 2023-03-28 | 斯托克制药公司 | 用于治疗疾患和疾病的opa1反义寡聚物 |
| EP4175956A1 (en) | 2020-07-02 | 2023-05-10 | Remix Therapeutics Inc. | 2-(indazol-5-yl)-6-(piperidin-4-yl)-1,7-naphthyridine derivatives and related compounds as modulators for splicing nucleic acids and for the treatment of proliferative diseases |
| EP4178963A1 (en) | 2020-07-02 | 2023-05-17 | Remix Therapeutics Inc. | 5-[5-(piperidin-4-yl)thieno[3,2-c]pyrazol-2-yl]indazole derivatives and related compounds as modulators for splicing nucleic acids and for the treatment of proliferative diseases |
| WO2022070071A1 (en) * | 2020-09-30 | 2022-04-07 | Janssen Biotech, Inc. | Dihydroorotate dehydrogenase inhibitors |
| BR112023018466A2 (pt) | 2021-03-17 | 2023-10-10 | Hoffmann La Roche | Derivados de tiazolopirimidinona |
| WO2023009585A2 (en) | 2021-07-28 | 2023-02-02 | Protego Biopharma, Inc. | Transthyretin stabilizing compounds |
| US20240368163A1 (en) | 2021-08-30 | 2024-11-07 | Remix Therapeutics Inc. | Compounds and methods for modulating splicing |
| IL311132A (en) | 2021-08-30 | 2024-04-01 | Remix Therapeutics Inc | Splicing Modulation Compounds and Methods |
| WO2023034836A1 (en) | 2021-08-30 | 2023-03-09 | Remix Therapeutics Inc. | Compounds and methods for modulating splicing |
| US20240400584A1 (en) | 2021-08-30 | 2024-12-05 | Remix Therapeutics Inc. | Compounds and methods for modulating splicing |
| WO2023034812A1 (en) | 2021-08-30 | 2023-03-09 | Remix Therapeutics Inc. | Compounds and methods for modulating splicing |
| WO2023064879A1 (en) | 2021-10-13 | 2023-04-20 | Remix Therapeutics Inc. | Compounds and methods for modulating nucleic acid splicing |
| CA3233973A1 (en) | 2021-10-13 | 2023-04-20 | Dominic Reynolds | Compounds and methods for modulating nucleic acid splicing |
| US20250109140A1 (en) | 2022-01-05 | 2025-04-03 | Remix Theraputics Inc. | 5-[5-(piperidin-4-yl)thieno[3,2-c]pyrazol-2-yl]indazole derivatives and related compounds as modulators for splicing nucleic acids and for the treatment of proliferative diseases |
| US20250326748A1 (en) | 2022-01-05 | 2025-10-23 | Remix Therapeutics Inc. | Compounds and methods for modulating splicing |
| WO2023133217A1 (en) | 2022-01-05 | 2023-07-13 | Remix Therapeutics Inc. | 2-(indazol-5-yl)-6-(piperidin-4-yl)-1,7-naphthyridine derivatives and related compounds as modulators for splicing nucleic acids and for the treatment of proliferative diseases |
| WO2023240236A1 (en) | 2022-06-10 | 2023-12-14 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of spinal muscular atrophy related disorders |
| WO2024251925A1 (en) * | 2023-06-09 | 2024-12-12 | F. Hoffmann-La Roche Ag | Inducible gene expression system |
| CN117263936B (zh) * | 2023-11-21 | 2024-02-23 | 中国中医科学院医学实验中心 | 一种咪唑并[1, 2-a]吡啶衍生物及其制备方法和在中枢神经系统渗透性HDAC6抑制药物中的应用 |
| WO2025233837A1 (en) | 2024-05-07 | 2025-11-13 | Takeda Pharmaceutical Company Limited | 4h-pyrimido[1,2-a]pyrimidin-4-one derivatives for use as nlrp3 inflammasome inhibitors for the treatment of neurodegenerative disorder |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3558618A (en) | 1968-04-01 | 1971-01-26 | Dow Chemical Co | Novel 4h-pyrazino(1,2-a)pyrimidine-4-ones |
| US4122274A (en) * | 1977-05-25 | 1978-10-24 | Bristol-Myers Company | 3-Tetrazolo-5,6,7,8-substituted-pyrido[1,2-a]pyrimidin-4-ones |
| JPS56150091A (en) | 1980-03-28 | 1981-11-20 | Janssen Pharmaceutica Nv | 3-(1-piperidinylalkyl)-4h-pyrido(1,2-a)pyrimidine- 4-one derivative and its manufacture |
| US4342870A (en) * | 1980-03-28 | 1982-08-03 | Janssen Pharmaceutica N.V. | Novel 3-(1-piperidinylalkyl)-4H-pyrido[1,2-a]pyrimidin-4-one derivatives |
| US5089633A (en) | 1987-04-28 | 1992-02-18 | Georgia Tech Research Corporation | Substituted isocoumarins |
| US5599816A (en) * | 1990-05-02 | 1997-02-04 | Abbott Laboratories | Quinolizinone type compounds |
| EP0640083A1 (en) | 1992-05-13 | 1995-03-01 | E.I. Du Pont De Nemours And Company | Substituted pyrido 1,2-a]pyrimidinone derivatives as fungicides |
| KR19990022524A (ko) | 1995-06-06 | 1999-03-25 | 웨인스톡 스티븐 에프. | 퀴놀리지논형화합물 |
| US5869500A (en) | 1996-12-13 | 1999-02-09 | Hoffmann-La Roche Inc. | Pyridone compounds useful in treating Alzheimer's disease |
| AU5991699A (en) * | 1998-09-21 | 2000-04-10 | Biochem Pharma Inc. | Quinolizinones as integrin inhibitors |
| WO2001030757A1 (en) * | 1999-10-28 | 2001-05-03 | Microcide Pharmaceuticals, Inc. | Drug discharge pump inhibitors |
| CN1891693A (zh) * | 2000-01-24 | 2007-01-10 | 基纳西亚股份有限公司 | 用于治疗的吗啉代基取代的化合物 |
| US20050009843A1 (en) | 2001-04-26 | 2005-01-13 | Kiyoshi Nakayama | Medicine for inhibiting drug elimination pump |
| ATE466581T1 (de) | 2001-12-07 | 2010-05-15 | Vertex Pharma | Verbindungen auf pyrimidin-basis als gsk-3-hemmer |
| GB0205281D0 (en) | 2002-03-06 | 2002-04-17 | Novartis Ag | Organic compounds |
| AU2003256755A1 (en) | 2002-07-24 | 2004-02-09 | Ptc Therapeutics, Inc. | Ureido substituted benzoic acid compounds, their use for nonsense suppression and the treatment of diseases caused by such mutations |
| CN1809563A (zh) * | 2003-06-20 | 2006-07-26 | 希龙公司 | 吡啶并[1,2－a]嘧啶－4－酮化合物用作抗癌药 |
| ATE373659T1 (de) | 2004-05-04 | 2007-10-15 | Warner Lambert Co | Pyrrolylsubstituierte pyrido(2,3-d)pyrimidin-7- one und derivate davon als therapeutische mittel |
| AU2006206446A1 (en) | 2005-01-21 | 2006-07-27 | Janssen Pharmaceutica N.V. | Novel heterocyclic benzo[c]chromene derivatives useful as modulators of the estrogen receptors |
| AR059339A1 (es) | 2006-02-09 | 2008-03-26 | Chugai Pharmaceutical Co Ltd | Derivados de la cumarina para trastornos proliferativos de celulas, composicion farmaceutica y agente terapeutico que los contiene |
| US8110681B2 (en) * | 2006-03-17 | 2012-02-07 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Compounds for the treatment of spinal muscular atrophy and other uses |
| US8337941B2 (en) | 2006-07-27 | 2012-12-25 | The Trustees Of Columbia University In The City Of New York | Fluorescent substrates for monoamine transporters as optical false neurotransmitters |
| WO2009151546A2 (en) * | 2008-05-27 | 2009-12-17 | Ptc Therapeutics, Inc. | Methods for treating spinal muscular atrophy |
| EP2138493A1 (en) * | 2008-06-26 | 2009-12-30 | Sanofi-Aventis | Substituted pyrimidone derivatives |
| WO2010019243A1 (en) | 2008-08-13 | 2010-02-18 | Ptc Therapeutics, Inc. | Methods for treating viral infections |
| WO2011050245A1 (en) * | 2009-10-23 | 2011-04-28 | Yangbo Feng | Bicyclic heteroaryls as kinase inhibitors |
| EP2501231B1 (en) * | 2009-11-20 | 2016-12-21 | Merck Sharp & Dohme Corp. | Quinolizidinone carboxamide m1 receptor positive allosteric modulators |
| CN102812023A (zh) * | 2010-01-13 | 2012-12-05 | 韩国巴斯德研究所 | 抗感染吡啶并(1,2-a)嘧啶类 |
| KR102057351B1 (ko) | 2011-12-30 | 2019-12-18 | 피티씨 테라퓨틱스, 인크. | 척수성 근위축증을 치료하기 위한 화합물 |
| PL2809322T3 (pl) | 2012-01-26 | 2019-11-29 | Ptc Therapeutics Inc | Związki do leczenia zaniku mięśni pochodzenia rdzeniowego |
| DK2812004T3 (en) * | 2012-02-10 | 2018-10-15 | Ptc Therapeutics Inc | COMPOUNDS FOR TREATMENT OF SPINAL MUSCLE DROPHY |
| CN104302181B (zh) | 2012-03-01 | 2017-09-15 | Ptc医疗公司 | 用于治疗脊髓性肌萎缩的化合物 |
| KR102109992B1 (ko) | 2012-03-23 | 2020-05-13 | 피티씨 테라퓨틱스, 인크. | 척수성 근위축증을 치료하기 위한 화합물 |
| SI3143025T1 (sl) | 2014-05-15 | 2020-01-31 | F. Hoffmann-La Roche Ag | Spojine za zdravljenje spinalne mišične atrofije |
| EP3298017B1 (en) | 2015-05-20 | 2019-08-14 | H. Hoffnabb-La Roche Ag | Compounds for treating spinal muscular atrophy |
-
2013
- 2013-02-08 DK DK13747100.9T patent/DK2812004T3/en active
- 2013-02-08 MX MX2014009696A patent/MX354074B/es active IP Right Grant
- 2013-02-08 WO PCT/US2013/025292 patent/WO2013119916A2/en not_active Ceased
- 2013-02-08 SG SG10201609188WA patent/SG10201609188WA/en unknown
- 2013-02-08 PH PH1/2018/501711A patent/PH12018501711B1/en unknown
- 2013-02-08 EP EP13747100.9A patent/EP2812004B1/en active Active
- 2013-02-08 NZ NZ628186A patent/NZ628186A/en unknown
- 2013-02-08 CN CN202411603136.1A patent/CN119528903A/zh active Pending
- 2013-02-08 CN CN201380019368.6A patent/CN104349777B/zh active Active
- 2013-02-08 TR TR2018/13877T patent/TR201813877T4/tr unknown
- 2013-02-08 AU AU2013216870A patent/AU2013216870B2/en active Active
- 2013-02-08 BR BR112014019750-4A patent/BR112014019750B1/pt active IP Right Grant
- 2013-02-08 ES ES13747100T patent/ES2697174T3/es active Active
- 2013-02-08 PL PL13747100T patent/PL2812004T3/pl unknown
- 2013-02-08 KR KR1020147025275A patent/KR102137087B1/ko active Active
- 2013-02-08 US US14/377,531 patent/US9586955B2/en active Active
- 2013-02-08 UA UAA201409921A patent/UA116981C2/uk unknown
- 2013-02-08 SG SG11201404713PA patent/SG11201404713PA/en unknown
- 2013-02-08 EA EA201792465A patent/EA037123B1/ru unknown
- 2013-02-08 CA CA2863874A patent/CA2863874C/en active Active
- 2013-02-08 EP EP18179491.8A patent/EP3406252B1/en active Active
- 2013-02-08 HU HUE13747100A patent/HUE039779T2/hu unknown
- 2013-02-08 KR KR1020207020788A patent/KR102341596B1/ko active Active
- 2013-02-08 CN CN201810234432.7A patent/CN108299314B/zh active Active
- 2013-02-08 JP JP2014556711A patent/JP6092897B2/ja active Active
- 2013-02-08 EA EA201491505A patent/EA029542B1/ru not_active IP Right Cessation
- 2013-02-08 PE PE2014001250A patent/PE20142364A1/es active IP Right Grant
- 2013-02-14 AR ARP130100450 patent/AR092794A1/es active IP Right Grant
- 2013-02-18 TW TW106106161A patent/TWI629274B/zh active
- 2013-02-18 TW TW102105672A patent/TWI585085B/zh active
-
2014
- 2014-08-05 IL IL233959A patent/IL233959A/en active IP Right Grant
- 2014-08-07 PH PH12014501786A patent/PH12014501786A1/en unknown
- 2014-08-08 CL CL2014002100A patent/CL2014002100A1/es unknown
- 2014-08-08 CR CR20140376A patent/CR20140376A/es unknown
- 2014-08-11 MX MX2022011699A patent/MX2022011699A/es unknown
- 2014-08-28 MA MA37313A patent/MA35920B1/fr unknown
- 2014-09-04 EC ECIEPI201417269A patent/ECSP14017269A/es unknown
- 2014-09-09 CO CO14198817A patent/CO7061082A2/es unknown
-
2016
- 2016-08-26 US US15/248,052 patent/US9879007B2/en active Active
-
2017
- 2017-02-09 JP JP2017022640A patent/JP6363744B2/ja active Active
- 2017-06-22 AU AU2017204248A patent/AU2017204248B2/en active Active
- 2017-08-17 IL IL254045A patent/IL254045B/en active IP Right Grant
- 2017-12-20 US US15/848,075 patent/US20180105526A1/en not_active Abandoned
-
2019
- 2019-08-15 US US16/541,401 patent/US10851101B2/en active Active
-
2020
- 2020-10-05 US US17/062,853 patent/US11753407B2/en active Active
-
2023
- 2023-07-26 US US18/359,209 patent/US20240067646A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015508075A5 (enExample) | ||
| JP2015504057A5 (enExample) | ||
| JP2020522570A5 (enExample) | ||
| JP2021519291A5 (enExample) | ||
| US11382918B2 (en) | Methods for treating Huntington's Disease | |
| EP3645121B1 (en) | Methods for treating huntington's disease | |
| JP2021528466A5 (enExample) | ||
| DK2812004T3 (en) | COMPOUNDS FOR TREATMENT OF SPINAL MUSCLE DROPHY | |
| JP2021528467A5 (enExample) | ||
| RU2019115115A (ru) | Производные пиперидина в качестве ингибиторов убиквитин-специфической протеазы 7 | |
| JP2011500774A5 (enExample) | ||
| JP2025533831A (ja) | Ｋｒａｓ ｇ１２ｃ変異タンパク質のテザー型複素環式阻害剤及びその使用 | |
| JP2021519318A5 (enExample) | ||
| JP2016537384A5 (enExample) | ||
| JP2013519707A5 (enExample) | ||
| JP2015511224A5 (enExample) | ||
| JP2019535664A5 (enExample) | ||
| KR20200033249A (ko) | 헌팅턴병 치료 화합물 | |
| AU2015296322A1 (en) | 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as CDK inhibitors and uses thereof | |
| JP2016504363A5 (enExample) | ||
| SI3083625T1 (en) | Pyrimidopyrimidinones, useful as Wee-1 kinase inhibitors | |
| ME02202B (me) | Jedinjenja pirolopirimidina kao inhibitori cdk4/6 | |
| RU2015131148A (ru) | СОЕДИНЕНИЯ, ГЕТЕРОБИЦИКЛО-ЗАМЕЩЕННЫЕ-[1, 2, 4]ТРИАЗОЛО[1, 5c]ХИНАЗОЛИН-5-АМИНА, ОБЛАДАЮЩИЕ СВОЙСТВАМИ А2А АНТАГОНИСТОВ | |
| JP2016529292A5 (enExample) | ||
| HRP20131122T1 (hr) | Derivati 1,2,4-triazolo[4,3-a] piridina i njihova uporaba u lijeäśenju ili prevenciji neuroloških i psihijatrijskih poremeä†aja |